Artia Global Partners LP Purchases New Position in Avalo Therapeutics, Inc. $AVTX

Artia Global Partners LP purchased a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 41,570 shares of the company’s stock, valued at approximately $755,000. Artia Global Partners LP owned approximately 0.22% of Avalo Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. BIT Capital GmbH purchased a new position in shares of Avalo Therapeutics in the 3rd quarter valued at about $25,000. PFS Partners LLC increased its stake in shares of Avalo Therapeutics by 100.0% in the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after purchasing an additional 1,000 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Avalo Therapeutics in the 3rd quarter valued at about $143,000. Boothbay Fund Management LLC purchased a new position in shares of Avalo Therapeutics in the 2nd quarter valued at about $56,000. Finally, Jump Financial LLC purchased a new position in shares of Avalo Therapeutics in the 4th quarter valued at about $238,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Trading Up 7.5%

NASDAQ:AVTX opened at $15.40 on Thursday. The company’s 50-day moving average price is $15.53 and its 200-day moving average price is $16.12. The company has a market cap of $809.58 million, a P/E ratio of -2.82 and a beta of 0.83. Avalo Therapeutics, Inc. has a twelve month low of $4.47 and a twelve month high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.02. On average, analysts expect that Avalo Therapeutics, Inc. will post -2.58 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on AVTX. Citizens Jmp cut their price target on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. BTIG Research reiterated a “buy” rating and set a $58.00 price objective on shares of Avalo Therapeutics in a research note on Tuesday. Wolfe Research began coverage on Avalo Therapeutics in a research note on Thursday, April 9th. They set an “outperform” rating and a $48.00 price objective for the company. Wedbush cut their price objective on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. Finally, Piper Sandler reiterated an “overweight” rating and set a $60.00 price objective (up from $48.00) on shares of Avalo Therapeutics in a research note on Monday, May 11th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Avalo Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $46.67.

Insider Activity

In other news, CFO Christopher Ryan Sullivan sold 8,457 shares of the company’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $13.23, for a total value of $111,886.11. Following the completion of the sale, the chief financial officer directly owned 423 shares in the company, valued at $5,596.29. This represents a 95.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $18.01, for a total value of $71,499.70. Following the completion of the sale, the insider owned 3,622 shares of the company’s stock, valued at $65,232.22. This trade represents a 52.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 112,586 shares of company stock worth $2,089,651 over the last ninety days. Corporate insiders own 4.46% of the company’s stock.

Avalo Therapeutics Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.